SCHEMBL1647367

SCHEMBL1647367

O=C(OCc1ccccc1F)c1cc(Br)ccc1OCc1ccccc1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.59
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
LMNA P02545 3/20 0.50
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 1/20 0.50
NPC1 O15118 4/20 0.49
TSHR P16473 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
GLA P06280 1/20 0.49
TDP1 Q9NUW8 1/20 0.47
PTGER1 P34995 1/20 0.47
POLB P06746 3/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
MAPT P10636 3/20 0.45
RAB9A P51151 3/20 0.45
HTT P42858 2/20 0.45
MMP1 P03956 1/20 0.45
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1646922 0.88 LRRK2 (0.62) LRRK2MEN1KMT2ALMNAALDH1A1
SCHEMBL1648028 0.86 MEN1 (0.52) LRRK2MEN1KMT2APTGER1
SCHEMBL1648024 0.85 LRRK2 (0.59) LRRK2MEN1KMT2ALMNAALDH1A1
SCHEMBL1646919 0.84 PTGER1 (0.52) LRRK2MEN1KMT2AALDH1A1KDM4E
SCHEMBL1647309 0.81 ALDH1A1 (0.55) LRRK2KMT2AALDH1A1KDM4ENPC1
SCHEMBL1647338 0.81 LRRK2 (0.50) LRRK2MEN1KMT2ALMNAALDH1A1
SCHEMBL552025 0.79 LRRK2 (0.57) LRRK2LMNAALDH1A1KDM4EL3MBTL1
SCHEMBL1646590 0.77 LRRK2 (0.58) LRRK2MEN1KMT2ALMNAPTGER1
SCHEMBL1648521 0.76 LRRK2 (0.56) LRRK2MEN1KMT2ALMNAKDM4E
SCHEMBL1646587 0.76 LRRK2 (0.60) LRRK2LMNAKDM4EMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2483254-B1 NOVEL COMPOUNDS GLAXO GROUP LTD (GB) 2014-08-13 EP disclosed
US-8778939-B2 Compounds GLAXO GROUP LIMITED (GB) 2014-07-15 US disclosed
EP-2483254-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2012-08-08 EP disclosed
US-20120184553-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-07-19 US disclosed
WO-2011038572-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2011-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184553-A1 NOVEL COMPOUNDS LRRK2, PARK7, PINK1 LRRK2 1/4885MEN1 4102/4885KMT2A 2336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.